American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients

Background: COVID-19 related acute illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in decisions about the use of anticoagulation in patients with COVID-19. Methods: ASH formed a multidisciplinary guideline panel, including patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including performing systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines. Results: The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk. The panel also noted that heparin (unfractionated or low-molecular-weight) may be preferred because of a preponderance of evidence with this class of anticoagulants. Conclusions: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.

[1]  M. Zeitlinger,et al.  Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis , 2021, Clinical pharmacology and therapeutics.

[2]  K. Thorpe,et al.  Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis , 2021, Research and Practice in Thrombosis and Haemostasis.

[3]  C. S. Kow,et al.  The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials , 2021, Journal of Infection and Chemotherapy.

[4]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[5]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[6]  R. Mehran,et al.  Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials , 2021, European heart journal. Cardiovascular pharmacotherapy.

[7]  E. Akl,et al.  American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients , 2021, Blood Advances.

[8]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[9]  P. Bruzzi,et al.  Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) , 2021, Infectious Diseases and Therapy.

[10]  A. Simonds,et al.  Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline , 2021, European Respiratory Journal.

[11]  H. Schünemann,et al.  American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 , 2021, Blood Advances.

[12]  M. Barish,et al.  Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19 , 2021, Research and Practice in Thrombosis and Haemostasis.

[13]  M. Egi,et al.  Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) , 2021, Acute medicine & surgery.

[14]  D. Jiménez,et al.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.

[15]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[16]  P. Prandoni,et al.  The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience , 2020, Journal of Thrombosis and Haemostasis.

[17]  I. Wijaya,et al.  Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary? , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[18]  R. Favory,et al.  Pulmonary Embolism in Patients With COVID-19 , 2020, Circulation.

[19]  G. Guyatt,et al.  Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. , 2020, Blood advances.

[20]  D. Radovanovic,et al.  Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study , 2020, Pharmacological Research.

[21]  H. Schünemann,et al.  A user guide to the American Society of Hematology clinical practice guidelines. , 2020, Blood advances.

[22]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[23]  S. Birocchi,et al.  Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? , 2020, Thrombosis and Haemostasis.

[24]  L. Mbuagbaw,et al.  Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. , 2020, Blood.

[25]  A. Klatsky,et al.  Lower risk of venous thromboembolism in multiple Asian ethnic groups , 2019, Preventive medicine reports.

[26]  G. Collins,et al.  PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies , 2019, Annals of Internal Medicine.

[27]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[28]  H. Schünemann,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.] , 2017, Recenti progressi in medicina.

[29]  Alonso Carrasco-Labra,et al.  GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.

[30]  Holger J Schünemann,et al.  Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. , 2015, Annals of internal medicine.

[31]  R. Goldberg,et al.  Secular Trends in Occurrence of Acute Venous Thromboembolism: The Worcester VTE Study (1985-2009) , 2015 .

[32]  S. Suissa,et al.  Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. , 2013, The American journal of medicine.

[33]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[34]  Günter Ollenschläger,et al.  Guidelines International Network: Toward International Standards for Clinical Practice Guidelines , 2012, Annals of Internal Medicine.

[35]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[36]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[37]  Theo Stijnen,et al.  Random effects meta‐analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data , 2010, Statistics in medicine.

[38]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[39]  G. Guyatt,et al.  Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group , 2004, BMC health services research.

[40]  Andrew D Oxman,et al.  Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[41]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[42]  W Penfield,et al.  University Medicine. , 1962, Canadian Medical Association journal.